Instromedix gets Japanese marketing approval:
This article was originally published in Clinica
The Japanese Ministry of Health and Welfare has approved Instromedix' (US) range of ambulatory cardiac event monitors for sale in Japan. The average hospital stay for cardiac care in Japan is 21 days, compared with seven in the US. At $16,700 million Japan is the third largest market for medtech products after the US and Europe.